Robert Grubb to Follow-Up Studies
This is a "connection" page, showing publications Robert Grubb has written about Follow-Up Studies.
Connection Strength
0.287
-
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol. 2013 Mar; 189(3):871-7.
Score: 0.065
-
Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol. 2006 Jun; 3(6):306-7.
Score: 0.042
-
Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020 04; 13(4):367-376.
Score: 0.027
-
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
Score: 0.025
-
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123(4):592-599.
Score: 0.022
-
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol. 2014 Jan; 16(1):123-30.
Score: 0.018
-
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013 Apr 01; 73(7):2211-20.
Score: 0.017
-
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
Score: 0.015
-
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):4314-20.
Score: 0.013
-
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
Score: 0.013
-
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
Score: 0.012
-
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
Score: 0.011
-
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
Score: 0.010